Many drugs, such as agents for cancer or autoimmune diseases, have nasty side effects because while they kill disease-causing cells, they also affect healthy cells. Now, a new study has demonstrated a technique for developing more targeted drugs, by using molecular “robots” to hone in on more specific populations of cells.
The Food and Drug Administration is warning consumers to avoid a vitamin B dietary supplement from Healthy Life Chemistry by Purity First because it contains two potentially dangerous anabolic steroids. The agency says the company's B-50 supplements tested positive for methasterone and and dimethazine.
Silk has walked straight off the runway and into the lab. According to a new study, silk implants placed in the brain of laboratory animals and designed to release a specific chemical, adenosine, may help stop the progression of epilepsy.
As the U.S. Food and Drug Administration (FDA) continues to finalize regulations to establish a pathway for approving biopharmaceutical or biosimilar drugs, leading branded drug manufacturers are looking ahead and lobbying state legislatures to enact laws that would limit the substitution of biogenerics for brand-name drugs.
Key molecular pathways that ultimately lead to late-onset Alzheimer’s disease, the most common form of the disorder, have been identified by researchers. The study, which used a combination of systems biology and cell biology tools, presents a new approach to Alzheimer’s disease research and highlights several new potential drug targets.
The discovery of a gene's function in E. coli and other bacteria might lead to a probiotic to prevent the most common type of kidney stone, according to a new study. The team made the discovery during a study of genes in Acetobacter aceti, a harmless bacterium that is typically used to convert wine to vinegar.
Researchers have unraveled the secret to byssus threads, the tiny natural bungee cords that mussels use to dangle loosely from rocks, piers or ships. Byssus threads, they found, are composed of a well-designed combination of soft, stretchy material on one end and much stiffer material on the other.
For the first time, scientists are working on developing a ‘nano-coating’ that would protect a vaccine from its environment both in transit and for storage. Using the latest chemistry advances, researchers hope to show how nano-silica can be grown around individual vaccine molecules, enabling a vaccine to be taken anywhere in the world without refrigeration.
An international team has determined and analyzed the three-dimensional atomic structure of the human glucagon receptor. The receptor, found mainly on liver and kidney cells, helps regulate glucose levels in the bloodstream and is the target of potential therapeutic agents for type 2 diabetes.
A research team has discovered a new chemical compound from an ocean microbe in a preliminary research finding that could one day set the stage for new treatments for anthrax and other ailments such as methicillin-resistant Staphylococcus aureus (MRSA).
An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier, kill tumor cells and block the growth of tumor blood vessels, according to a new study. The laboratory and animal study also shows how the agent, called SapC-DOPS, targets tumor cells and blood vessels.
Technological advancements of analytical instrumentation platforms coupled with demand for higher sensitivity in many life science applications have led to a critical need for significant improvement in the cleanliness of plastic consumables.
A drug already approved to treat multiple sclerosis may also hold promise for treating cardiac hypertrophy, or thickening of the cardiac muscle, a disorder that often leads to heart failure, researchers report. Cardiac hypertrophy, which afflicts one in 500 people, can be caused by high blood pressure or inherited through genes that control contraction of the heart.
An international group of scientists has shown that a drug candidate designed by scientists significantly increases exercise endurance in animal models. These findings could lead to new approaches to helping people with conditions that acutely limit exercise tolerance.
Children who suffer from arthritis could one day receive more targeted treatment thanks to potential markers for the severity of the disorder. The early results of a world-first study looking have shown that changes in the levels of particular molecules known as prostanoids in the blood of these patients may predict the course of arthritis more accurately and help provide more individualized treatment.
A recent survey from the International Data Corporation (IDC) suggests that knowledge workers spend 15-35% of their time searching for information. A previous study by the same firm estimated that an enterprise with 1,000 knowledge workers loses a minimum of $6 million a year in the time workers spend searching for, and not finding, needed information. These types of issues are very relevant in the pharmaceutical and chemical industries.
Paralytic drugs like succinylcholine (SC) are often used during surgery or when critically ill patients require endotracheal intubation. But if the drug is not swiftly cleared from the patient’s system, the results can be deadly. A new study shows that the plant-produced recombinant human enzyme butyrylcholinesterase (BChE) can rapidly reverse paralysis of the airways (or apnea) caused by succinylcholine.
Scientists have identified two promising candidates for the development of drugs against human adenovirus, a cause of ailments ranging from colds to gastrointestinal disorders to pink eye. The researchers sifted through thousands of compounds to determine which might block the effects of a key viral enzyme they had previously studied in atomic-level detail.
An existing FDA-approved drug improves cognitive function in a mouse model of Down syndrome, according to a new study. The drug, an asthma medication called formoterol, strengthened nerve connections in the hippocampus, a brain center used for spatial navigation, paying attention and forming new memories, the study says.
Doctors’ ability to predict which drugs will work with individual patients may be influenced by recent University of Missouri research that found seemingly identical neurons can behave the same even though they are built differently under the surface.
Recent studies, however, suggest that the real culprit behind Alzheimer’s may be small Aβ clumps called oligomers that appear in the brain years before plaques develop. In unraveling oligomers’ molecular structure, scientists discovered that Aβ has a vastly different organization in oligomers than in amyloid plaques.
AstraZeneca announced that its new UK-based global research and development center and corporate headquarters will be located at the Cambridge Biomedical Campus on the southern outskirts of the city. By 2016, the new site will house a workforce of approximately 2,000.
The first experimental drug to boost brain synapses lost in Alzheimer’s disease has been developed by researchers. The drug, called NitroMemantine, combines two FDA-approved medicines to stop the destructive cascade of changes in the brain that destroys the connections between neurons, leading to memory loss and cognitive decline.
A pair of researchers who in the past created compounds to block the SARS virus are now tackling the new Middle East respiratory syndrome coronavirus, or MERS-CoV. The team's successful work on SARS paved the way for them to swiftly work on MERS CoV, reducing parts of the process that would normally take years to a matter of month.
Researchers eradicated most melanoma tumors by exposing them to a fast-acting virus, according to a report in the Journal of Virology. Melanoma is the deadliest type of skin cancer and can spread throughout the body and even into the brain.